From Parasite to Pill: Harnessing Biology for Breakthroughs in Antimalarial Drug Discovery

The global imperative for malaria eradication demands innovative strategies for antimalarial drug discovery, particularly in the face of growing drug resistance. This article describes how biological insights into Plasmodium parasites and their interactions with the human host are transforming the antimalarial drug discovery landscape. We examine the parasite's complex life cycle and its unique metabolic pathways and organelles as potential sources of drug targets. We demonstrate how advances in omics technologies and gene-editing tools are revolutionizing our understanding of parasite biology and accelerating target identification. Novel approaches to overcoming existing resistance mechanisms, with improved methods for predicting and preventing drug resistance, are presented, while promising new drug targets are discussed, as well as emerging approaches to target dormant forms of the parasite. The potential of host-directed therapies is explored together with notable case studies that highlight recent successes in biologically driven drug discovery efforts. The future of the field must embrace artificial intelligence, pharmacogenomics, and collaborative innovation anchored in ethical and equitable frameworks, to maximize global health impact.